Drug intelligence / Profile preview

gemcitabine + TheraSphere

Development stage
Unknown
Lead developer
Boston Scientific
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous, Intra-arterial
01

Overview

A combination therapy consisting of gemcitabine, a nucleoside analog chemotherapeutic agent, and TheraSphere, a yttrium-90 (Y-90) glass microsphere radioembolization treatment. This combination approach aims to provide both systemic chemotherapy via gemcitabine and targeted radiation therapy to liver tumors through TheraSphere. It has been investigated in clinical trials for treating hepatic metastases from pancreatic cancer and intrahepatic cholangiocarcinoma.

Brand names
GemzarTheraSphere
Other names
Gemcitabine with TheraSphereGemcitabine + Y-90 TheraSphereGemcitabine plus yttrium-90 radioembolization
02

Targets

ENT (Equilibrative nucleoside transporter family)DNA polymerase familyRNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on gemcitabine + TheraSphere.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + TheraSphere.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call